Community/Retail

Proper reporting of errors and near misses helps maintain compliance and improve patient safety.

Researchers recommend early vaccination against herpes zoster to mitigate the risks.

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Patient education on the risks of the long-term illness can help overcome vaccine hesitancy.

Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.

Short-term spinal cord stimulation could provide long-term pain relief and improve the overall quality of life for individuals with herpes zoster-associated pain and postherpetic neuralgia.

The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.

The 2025 GOLD Report emphasizes the importance of tailoring combination treatments based on patient factors like eosinophil counts and exacerbation history.

The nasal spray label resembles that of the FDA-approved epinephrine injection, leading to potential dosing errors.

Pharmacists can help address nicotine addiction by recommending FDA-approved smoking cessation methods and educating on the risks associated with electronic cigarette use.

Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.

Providing crucial information allows patients to take charge of their treatments.

VGT-1849A could reduce JAK2 activity, lessening the disease burden faced by individuals with PV while providing a favorable safety profile.

Rates of GBS were similar between Arexvy and Abrysvo, at 0.12% and 0.11% of total reported events, respectively.

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

OraQuick was the first at-home HIV test kit to be approved by the FDA in 2012.

The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

Varicella-zoster vaccination could prevent fatal outcome among individuals with disseminated herpes zoster.

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.

This could be attributed to improved diet and health awareness.

The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.

New mechanisms of action are proving more effective than ever, offering slowed progression.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.

Duloxetine is a commonly prescribed medication used to treat anxiety, depression, and other mental health disorders.

In this episode of Public Health Matters, Christina Madison discusses the concept of reproductive justice and ensuring Black maternal health efforts are not left behind with Regina Davis Moss of In Our Own Voice.

Lerodalcibep is a third-generation PCSK9 inhibitor that demonstrated success in reducing low density lipoprotein cholesterol (LDL-C).